*The Prenuvo whole-body MRI screening:
The Prenuvo whole-body MRI screening: (1) can serve as an adjunct to, but is not intended to replace, other established evidence–based screening practices for early detection of specific malignancies (e.g. colonoscopy, dedicated breast imaging, Pap-smear screening for cervical cancer, low-dose chest CT for high risk patients), (2) may not detect some very small cancers that happen to have an MRI appearance very similar to nearby normal tissue structures. We can generally identify cancerous lesions once they are approximately one centimeter in size, although the size limit of detection varies and may be lower in some parts of the body (e.g. the brain) and higher in other parts (e.g. the chest). Our method may not detect lesions in the lining tissue (mucosa) of various body parts, including the mouth, nose, throat, and gastrointestinal tract. As with any medical test, there are limitations, which make it impossible to detect all malignancies and disease conditions, (3)t does not evaluate the heart or heart vessels, (5) does not evaluate detailed lung microarchitecture or pulmonary micronodules, (6) does not replace dedicated breast imaging for screening or diagnostic evaluation (e.g. mammography, breast ultrasound, breast MRI with contrast), (7) is limited in the evaluation of the gastrointestinal tract and does not replace endoscopy or colonoscopy (e.g. cannot detect gastrointestinal polyps), (8) is limited in its assessment of the large joints as the exam is not tailored for detailed evaluation of the joint ligaments, cartilage, menisci, and labrum, (9) should not be considered a primary screening modality of the skin – this is best assessed by direct physical examination, (10) does not visualize smaller brain vessels – as with any imaging test, there are limitations, and stenosis or certain blood flow abnormalities may not be detected, (11) is not intended to replace dedicated diagnostic imaging in the setting of specific clinical diagnostic questions.
